TY - JOUR
T1 - The present and future of gastroenterology and hepatology
T2 - an international SWOT analysis (the GASTROSWOT project)
AU - de-Madaria, Enrique
AU - Mira, José J.
AU - Carrillo, Irene
AU - Afif, Waqqas
AU - Ang, Daphne
AU - Antelo, Marina
AU - Bollipo, Steven
AU - Castells, Antoni
AU - Chahal, Prabhleen
AU - Heinrich, Henriette
AU - Law, Joanna K.
AU - van Leerdam, Monique E.
AU - Lens, Sabela
AU - Pannala, Rahul
AU - Park, San Hyoung
AU - Rabiee, Atoosa
AU - Savarino, Edoardo V.
AU - Singh, Vikesh K.
AU - Vargo, John
AU - Charabaty, Aline
AU - Drenth, Joost P.H.
N1 - Funding Information:
The GASTROSWOT team thanks the Spanish Association of Gastroenterology for endorsing the project.
Funding Information:
EdM is a consultant for Takeda Pharmaceutical Company, Abbott, and Mylan. WA received consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Dynacare, Janssen, Merck, Novartis, Pfizer, Sandoz, and Takeda. SL received speaker and advisor fees from Gilead and AbbVie, and grants from Gilead. RP is a consultant to HCL Technologies, and on the scientific advisory board at Nestlé. VKS is consultant to AbbVie and Nestlé Health Science and has received grant funding from Orgenesis and Theraly. JV is a consultant to Olympus America, and on the scientific advisory board at Aspero Medical. AC consults for, is on the advisory board of, and has received education grants from from AbbVie, Takeda, Janssen, and Pfizer. The Radboud University Medical Center, on behalf of JPHD, received honoraria or research grants from Gilead and AbbVie. All other authors declare no competing interests.
Publisher Copyright:
© 2022
PY - 2022/5
Y1 - 2022/5
N2 - GASTROSWOT is a strategic analysis of the current and projected states of the different subspecialties in gastroenterology that aims to provide guidance for research, clinical, and financial planning in gastroenterology. We executed a consensus-based international strengths, weaknesses, opportunities, and threats (SWOT) analysis. Four general coordinators, six field coordinators, and 12 experts participated in the study. SWOTs were provided for the following fields: neurogastroenterology, functional gastrointestinal disorders, and upper gastrointestinal diseases; inflammatory bowel disease; pancreatology and biliary diseases; endoscopy; gastrointestinal oncology; and hepatology. The GASTROSWOT analysis highlights the following in the current state of the field of gastroenterology: the incidence and complexity of several gastrointestinal diseases, including malignancies, are increasing; the COVID-19 pandemic has affected patient care on several levels; and with the advent of technical innovations in gastroenterology, a well trained workforce and strategic planning are required to optimise health-care utilisation. The analysis calls attention to the following in the future of gastroenterology: artificial intelligence and the use of big data will speed up discovery and smarter health-care provision in the field; the growth and diversification of gastroenterological specialties will improve specialised care for patients, but could promote fragmentation of care and health system inefficiencies; and furthermore, thoughtful planning is needed to reach an effective balance between the need for subspecialists and the value of general gastroenterology services.
AB - GASTROSWOT is a strategic analysis of the current and projected states of the different subspecialties in gastroenterology that aims to provide guidance for research, clinical, and financial planning in gastroenterology. We executed a consensus-based international strengths, weaknesses, opportunities, and threats (SWOT) analysis. Four general coordinators, six field coordinators, and 12 experts participated in the study. SWOTs were provided for the following fields: neurogastroenterology, functional gastrointestinal disorders, and upper gastrointestinal diseases; inflammatory bowel disease; pancreatology and biliary diseases; endoscopy; gastrointestinal oncology; and hepatology. The GASTROSWOT analysis highlights the following in the current state of the field of gastroenterology: the incidence and complexity of several gastrointestinal diseases, including malignancies, are increasing; the COVID-19 pandemic has affected patient care on several levels; and with the advent of technical innovations in gastroenterology, a well trained workforce and strategic planning are required to optimise health-care utilisation. The analysis calls attention to the following in the future of gastroenterology: artificial intelligence and the use of big data will speed up discovery and smarter health-care provision in the field; the growth and diversification of gastroenterological specialties will improve specialised care for patients, but could promote fragmentation of care and health system inefficiencies; and furthermore, thoughtful planning is needed to reach an effective balance between the need for subspecialists and the value of general gastroenterology services.
UR - http://www.scopus.com/inward/record.url?scp=85127506884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127506884&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(21)00442-8
DO - 10.1016/S2468-1253(21)00442-8
M3 - Review article
C2 - 35247318
AN - SCOPUS:85127506884
SN - 2468-1253
VL - 7
SP - 485
EP - 494
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 5
ER -